Tags

Type your tag names separated by a space and hit enter

Protective effect of gonadotropin-releasing hormone agonist against chemotherapy-induced ovarian dysfunction: A meta-analysis.
Oncol Lett 2019; 17(6):5319-5326OL

Abstract

The protective effects of gonadotropin-releasing hormone agonist (GnRHa) against ovarian chemotherapy induced-toxicity have not completely been demonstrated and the impact of chemotherapy on ovarian dysfunction remains unclear. The present meta-analysis aimed to evaluate the efficiency of GnRHa and to determine whether GnRHa could influence the long-term survival rate of patients with cancer. A total of 12 clinical randomized controlled trials were included, consisting of 1,413 patients who were divided into the GnRHa group (n=705) and the control group (n=708). The meta-analysis revealed that GnRHa may significantly improve the menstrual function recovery rate in patients who received chemotherapy [RR=1.29, 95% confidence interval (CI)=1.09-1.54, P=0.004] and reduce the rate of premature ovarian failure (RR=0.47, 95% CI=0.31-0.71, P=0.0004). However, it had no effect on the pregnancy rate (RR=1.40, 95% CI=0.98-1.98, P=0.06), on the rate of disease-free survival and overall survival of patients (disease-free survival rate: RR=1.04, 95% CI=0.95-1.13, P=0.40; overall survival rate: RR=1.02, 95% CI=0.90-1.16, P=0.72). In conclusion, GnRHa may reduce chemotherapy-induced ovarian dysfunction without compromising or influencing the therapeutic effects of chemotherapy.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Family Planning Service Center of Yiwu Maternity and Child Health Care Hospital, Yiwu, Zhejiang 322000, P.R. China.Department of Obstetrics and Gynecology, Family Planning Service Center of Yiwu Maternity and Child Health Care Hospital, Yiwu, Zhejiang 322000, P.R. China.Department of Galactophore, Family Planning Service Center of Yiwu Maternity and Child Health Care Hospital, Yiwu, Zhejiang 322000, P.R. China.Department of Obstetrics and Gynecology, Family Planning Service Center of Yiwu Maternity and Child Health Care Hospital, Yiwu, Zhejiang 322000, P.R. China.Department of Human Health and Human Service, Family Planning Service Center of Yiwu Maternity and Child Health Care Hospital, Yiwu, Zhejiang 322000, P.R. China.Department of Public Health, Southwest Medical University, Luzhou, Sichuan 646600, P.R. China.Department of Obstetrics and Gynecology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050035, P.R. China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31186748

Citation

Zheng, Fei, et al. "Protective Effect of Gonadotropin-releasing Hormone Agonist Against Chemotherapy-induced Ovarian Dysfunction: a Meta-analysis." Oncology Letters, vol. 17, no. 6, 2019, pp. 5319-5326.
Zheng F, Zhu B, Feng Q, et al. Protective effect of gonadotropin-releasing hormone agonist against chemotherapy-induced ovarian dysfunction: A meta-analysis. Oncol Lett. 2019;17(6):5319-5326.
Zheng, F., Zhu, B., Feng, Q., Wu, L., Cui, Y., Liu, Y., & Wang, Y. (2019). Protective effect of gonadotropin-releasing hormone agonist against chemotherapy-induced ovarian dysfunction: A meta-analysis. Oncology Letters, 17(6), pp. 5319-5326. doi:10.3892/ol.2019.10252.
Zheng F, et al. Protective Effect of Gonadotropin-releasing Hormone Agonist Against Chemotherapy-induced Ovarian Dysfunction: a Meta-analysis. Oncol Lett. 2019;17(6):5319-5326. PubMed PMID: 31186748.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Protective effect of gonadotropin-releasing hormone agonist against chemotherapy-induced ovarian dysfunction: A meta-analysis. AU - Zheng,Fei, AU - Zhu,Bin, AU - Feng,Qingjing, AU - Wu,Lili, AU - Cui,Yuechong, AU - Liu,Yumo, AU - Wang,Yingqian, Y1 - 2019/04/15/ PY - 2018/04/28/received PY - 2018/12/19/accepted PY - 2019/6/13/entrez PY - 2019/6/13/pubmed PY - 2019/6/13/medline KW - chemotherapy KW - gonadotropin-releasing hormone agonist KW - meta-analysis KW - ovarian dysfunction SP - 5319 EP - 5326 JF - Oncology letters JO - Oncol Lett VL - 17 IS - 6 N2 - The protective effects of gonadotropin-releasing hormone agonist (GnRHa) against ovarian chemotherapy induced-toxicity have not completely been demonstrated and the impact of chemotherapy on ovarian dysfunction remains unclear. The present meta-analysis aimed to evaluate the efficiency of GnRHa and to determine whether GnRHa could influence the long-term survival rate of patients with cancer. A total of 12 clinical randomized controlled trials were included, consisting of 1,413 patients who were divided into the GnRHa group (n=705) and the control group (n=708). The meta-analysis revealed that GnRHa may significantly improve the menstrual function recovery rate in patients who received chemotherapy [RR=1.29, 95% confidence interval (CI)=1.09-1.54, P=0.004] and reduce the rate of premature ovarian failure (RR=0.47, 95% CI=0.31-0.71, P=0.0004). However, it had no effect on the pregnancy rate (RR=1.40, 95% CI=0.98-1.98, P=0.06), on the rate of disease-free survival and overall survival of patients (disease-free survival rate: RR=1.04, 95% CI=0.95-1.13, P=0.40; overall survival rate: RR=1.02, 95% CI=0.90-1.16, P=0.72). In conclusion, GnRHa may reduce chemotherapy-induced ovarian dysfunction without compromising or influencing the therapeutic effects of chemotherapy. SN - 1792-1074 UR - https://www.unboundmedicine.com/medline/citation/31186748/Protective_effect_of_gonadotropin-releasing_hormone_agonist_against_chemotherapy-induced_ovarian_dysfunction:_A_meta-analysis L2 - https://www.ingentaconnect.com/openurl?genre=article&issn=1792-1074&volume=17&issue=6&spage=5319&aulast=Zheng DB - PRIME DP - Unbound Medicine ER -